Offering user-friendly, authoritative guidance on cutting-edge psychopharmacologic and somatic treatments for psychiatric and neurologic conditions, Massachusetts General Hospital Psychopharmacology and Neurotherapeutics, 2nd Edition, helps you put today's best approaches to work for your patients. Composed of [RM1] topical chapters primarily from the third edition of Stern et al.'s Massachusetts General Hospital Comprehensive Clinical Psychiatry, this fully revised resource focuses on current psychotropic treatments, electroconvulsive therapy, and neurotherapeutics, making it an ideal quick reference for psychiatrists, psychologists, internists, and nurse practitioners. [RM1]Dr. Stern asked for "Comprised by" but comprised is a tricky word (I would typically say "comprised of," but that's also questionable), so can we change this to "Composed of"? Brings you up-to-date information on key topics in the field, including the application of anticonvulsants, anxiolytics, mood stabilizers, and psychostimulants; drug-drug interactions; side effects; treatment adherence; and more. Includes detailed coverage of antidepressants, antipsychotics, and antianxiety medications, as well as advances in caring for patients with treatment-resistant depression and new legal considerations when prescribing psychotropics. Covers recent progress on the use of neurotherapeutic interventions, such as transcranial magnetic stimulation, vagal nerve stimulation, and deep brain stimulation. Contains a new chapter on the pharmacotherapy of movement disorders (derived from Stern et al.'s MGH Handbook of General Hospital Psychiatry, 8th Edition). Features a user-friendly, highly templated format with abundant boxed summaries, bulleted points, case histories, algorithms, updated references, and suggested readings. Offers updated DSM-5-TR criteria alongside peerless, hands-on advice from members of the esteemed MGH Department of Psychiatry. An eBook version is included with purchase. The eBook allows you to access all of the text, figures, and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date. Includes clinical and research updates on: the application of a variety of medication classes (e.g., antidepressants, anticonvulsants, antipsychotics, anxiolytics, mood stabilizers, psychostimulants, psychedelics) advances in the treatment of treatment-resistant depression (e.g., the use of ketamine, electroconvulsive therapy, transcranial magnetic stimulation) progress on the use of neurotherapeutic interventions (e.g., vagal nerve stimulation, deep brain stimulation) legal considerations when prescribing psychotropics (e.g., informed consent, black box warnings) Plus a new chapter on clinical and research applications of psychedelics